BIOHM

Serial Number 87274467
Registration 5531063
702

Registration Progress

Application Filed
Dec 20, 2016
Under Examination
May 1, 2018
Approved for Publication
Mar 6, 2018
Published for Opposition
Mar 6, 2018
Registered
Jul 31, 2018

Basic Information

Serial Number
87274467
Registration Number
5531063
Filing Date
December 20, 2016
Registration Date
July 31, 2018
Published for Opposition
March 6, 2018
Drawing Code
4

Status Summary

Current Status
Active
Status Code
702
Status Date
Jan 2, 2025
Registration
Registered
Classes
005

Rights Holder

BIOHM HEALTH INC.

99
Address
425 LITERARY ROAD
SUITE 100
CLEVELAND, OH 44113

Ownership History

PathoBiome LLC

Original Applicant
16
Cleveland, OH

PathoBiome LLC

Owner at Publication
16
Cleveland, OH

PathoBiome LLC

Original Registrant
16
Cleveland, OH

BIOHM HEALTH LLC

New Owner After Registration #1
16
Cleveland, OH

BIOHM HEALTH INC.

New Owner After Registration #2
99
CLEVELAND, OH

Legal Representation

Attorney
BRIAN E. TURUNG
USPTO Deadlines 2 active 2 overdue
Deadline Type Event Code Deadline Date Days Until Priority Extension Available
OPPOSITION
Notice of Publication
NPUB Apr 05, 2018 2650 days overdue Medium Until May 05, 2018
ITU SOU
Notice of Allowance Mailed - SOU Required
NOAM Nov 01, 2018 2440 days overdue High Until May 01, 2019

Application History

50 events
Date Code Type Description
Jan 2, 2025 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jan 2, 2025 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Dec 31, 2024 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jul 31, 2024 E815 I TEAS SECTION 8 & 15 RECEIVED
Jul 31, 2023 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Feb 15, 2023 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 22, 2020 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 22, 2020 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 22, 2020 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Nov 22, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 22, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 22, 2020 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 30, 2019 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 31, 2018 R.PR A REGISTERED-PRINCIPAL REGISTER
Jun 26, 2018 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jun 25, 2018 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 31, 2018 SUPC I STATEMENT OF USE PROCESSING COMPLETE
May 31, 2018 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 9, 2018 IUAF S USE AMENDMENT FILED
May 9, 2018 EISU I TEAS STATEMENT OF USE RECEIVED
May 1, 2018 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 6, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 6, 2018 PUBO A PUBLISHED FOR OPPOSITION
Feb 14, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 31, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 4, 2017 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 4, 2017 GNSL S LETTER OF SUSPENSION E-MAILED
Nov 4, 2017 CNSL R SUSPENSION LETTER WRITTEN
Oct 17, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 17, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 16, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 25, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 25, 2017 GNRT O NON-FINAL ACTION E-MAILED
Sep 25, 2017 CNRT R NON-FINAL ACTION WRITTEN
Sep 25, 2017 RMRF Z REMOVE FROM TEASRF
Aug 30, 2017 ACEC I AMENDMENT FROM APPLICANT ENTERED
Aug 30, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 28, 2017 ALIE A ASSIGNED TO LIE
Aug 8, 2017 MAIL I PAPER RECEIVED
Jul 17, 2017 CNSL R SUSPENSION LETTER WRITTEN
Jul 17, 2017 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 17, 2017 GNSL S LETTER OF SUSPENSION E-MAILED
Jun 21, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 20, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 20, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 27, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 27, 2017 CNRT R NON-FINAL ACTION WRITTEN
Mar 27, 2017 GNRT F NON-FINAL ACTION E-MAILED
Mar 21, 2017 DOCK D ASSIGNED TO EXAMINER
Dec 28, 2016 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Detailed Classifications

Class 005
Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use, and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome
First Use Anywhere: Mar 1, 2017
First Use in Commerce: Mar 1, 2017

Classification

International Classes
005